Analysts expect Dextera Surgical Inc. (NASDAQ:DXTR) to post ($0.06) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Dextera Surgical’s earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.07). Dextera Surgical reported earnings of ($0.44) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 86.4%. The company is expected to announce its next quarterly earnings results on Monday, November 6th.

On average, analysts expect that Dextera Surgical will report full-year earnings of ($0.24) per share for the current year, with EPS estimates ranging from ($0.27) to ($0.20). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.19) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Dextera Surgical.

Dextera Surgical (NASDAQ:DXTR) last released its quarterly earnings results on Tuesday, August 8th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.29. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.03 million.

Several analysts have recently issued reports on the stock. Ladenburg Thalmann Financial Services assumed coverage on shares of Dextera Surgical in a research report on Wednesday. They set a “buy” rating and a $0.80 target price on the stock. Zacks Investment Research cut shares of Dextera Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Finally, Wedbush decreased their target price on shares of Dextera Surgical from $3.50 to $0.70 and set an “outperform” rating on the stock in a research report on Wednesday, July 12th.

An institutional investor recently bought a new position in Dextera Surgical stock. Perkins Capital Management Inc. acquired a new position in Dextera Surgical Inc. (NASDAQ:DXTR) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 333,983 shares of the medical instruments supplier’s stock, valued at approximately $100,000. Perkins Capital Management Inc. owned approximately 3.74% of Dextera Surgical at the end of the most recent reporting period. 7.41% of the stock is owned by institutional investors and hedge funds.

Dextera Surgical (DXTR) traded up 12.00% during midday trading on Wednesday, reaching $0.28. The company’s stock had a trading volume of 3,750,727 shares. The firm has a 50 day moving average price of $0.27 and a 200 day moving average price of $0.68. The firm’s market cap is $2.50 million. Dextera Surgical has a one year low of $0.17 and a one year high of $2.44.

TRADEMARK VIOLATION WARNING: “” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/1494637-2/1494637.html.

Dextera Surgical Company Profile

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Get a free copy of the Zacks research report on Dextera Surgical (DXTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dextera Surgical (NASDAQ:DXTR)

Receive News & Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.